There has been a growing trend of life science manufacturers collaborating with local governments (e.g., at the municipal and prefectural level) in Japan during the past 3-5 years. This trend is observed not only with domestic manufacturers but among foreign…
HOME > BUSINESS
BUSINESS
- Biosimilars Likely to Gain Further Impetus from Govt Push; Forteo/Enbrel Hit 40% Share, Herceptin 50%-Plus
June 22, 2022
- Alinamin Invites New President from Non-Pharma Sector
June 22, 2022
- Tokyo Wholesaler Slapped with 10-Day Biz Suspension over Fake Triazolam API
June 22, 2022
- Taiho Lifts Shipment Control on Abraxane
June 21, 2022
- ASKA Licenses Korean Rights for Birth Control Pill Drospirenone
June 21, 2022
- Astellas Workforce Down by More than 700: Securities Report
June 21, 2022
- PeptiDream Set to Develop Peptide-RI Conjugates for Refractory Cancers, Eyes No. 1 Spot in Radiotherapy
June 20, 2022
- Kyorin Snags Rights to Genetically Modified Adipocytes for Fabry Disease
June 20, 2022
- EMA Starts Review of Aripiprazole 2-Month Injectable: Otsuka/Lundbeck
June 20, 2022
- Kissei-Originated Fibroid Drug Approved in Europe
June 20, 2022
- Samsca Authorized Generic Hits Shelves in Japan
June 20, 2022
- Taisho’s Lusefi OD Film Now Available in Japan
June 20, 2022
- Takeda Founding Family to Vote against Foreign Leadership
June 17, 2022
- Patent Rows Don’t Stop Generic Players; Single Entries, AG Non-Launches Seen in June Listing
June 17, 2022
- Nihon Medi-Physics Launches AMED-Funded Project to Develop Antibody-RI Conjugates
June 16, 2022
- Ajovy Auto-Injector Approved in Japan: Otsuka
June 16, 2022
- Shionogi to Expand Access for Cefiderocol in Low- and Middle-Income Nations
June 16, 2022
- Asahi Kasei Snags Rights to Tsukuba Upstart’s CKD Drug Candidate
June 15, 2022
- Daiichi Sankyo Kicks Off PIII to Test ADC Follow-Up for Triple-Negative Breast Cancer
June 15, 2022
- Sanofi Set for Dupixent’s Pediatric Eczema Filing in Japan after Positive Data
June 15, 2022
ページ
Shionogi’s COVID-19 pill ensitrelvir failed to clear the second round of review by a key advisory panel on July 20. The session drew a great deal of attention since the drug is the first candidate for the application of Japan’s…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…